復旦張江(01349.HK):注射用FZ-AD005抗體偶聯劑用於治療晚期實體瘤獲得藥物臨牀試驗申請受理通知書
格隆匯10月20日丨復旦張江(01349.HK)公佈,公司收到國家藥品監督管理局核准簽發的《受理通知書》,注射用 FZ-AD005 抗體偶聯劑(即抗 DLL3抗體偶聯 BB05,"該藥物")用於治療晚期實體瘤的藥物 I 期臨牀試驗申請獲得受理。
近年來,公司在小分子端構建了全新的擁有自主知識產權的Linker-Drug平台("BB05平台 ")。該藥物是公司BB05平台第三個新一代抗體偶聯藥物(antibody-drug conjugate,ADC),由重組人鼠嵌合抗("DLL3")單克隆抗體與BB05偶聯組成。據公開資料顯示,該藥物是目前首個DLL3靶點的拓撲異構酶抑制劑類ADC藥物,其可通過與DLL3陽性的腫瘤細胞結合並內吞,在溶酶體內通過蛋白酶剪切定向釋放小分子細胞毒藥物(拓撲異構酶I抑制劑),殺傷腫瘤細胞。該藥物擬用於治療晚期實體瘤,包括但不限於小細胞肺癌、大細胞神經內分泌癌、前列腺癌等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.